At the end of 2018, Celgene understated the monotherapy of CD47 monoclonal antibody CC-90002 for the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). On the day of the suspension of the CC-90002 trial, shares in other CD47 companies such as Trillium, Forty Seven, and Surface… Continue Reading Second generation CD47 antibody: a new hot spot for tumor immunotherapy
Metabolism involves a series of biochemical reactions that convert nutrients into metabolites that play an important role in maintaining cellular homeostasis and in response to intracellular and extracellular stimuli. Metabolic changes are one of the important features of tumors. In order to maintain sustained proliferation, tumor cells must adjust… Continue Reading The next wave of cancer immunotherapy – regulating metabolism
Drug: NKG2A antibody Magazine: Cell & Nature Highlights: Cancer immunotherapy has a new target – NKG2A, I / II clinical trial data “giving expectations”, but the future is still unclear In recent years, cancer immunotherapy has achieved unprecedented success, but only a few patients have shown lasting efficacy. Improving… Continue Reading A new target for cancer immunotherapy – NKG2A, the future is unknown
Drug: CAR-T therapy Magazine: Nature Highlights: A clever design that increases the anti-cancer ability of CAR-T therapy More and more cancer patients are being treated with CAR-T cell therapy. CAR, the English full name of Chimeric Antigen Receptor, chimeric antigen receptor, is a kind of “navigation” that… Continue Reading Upgraded version of CAR-T therapy, greatly improved anti-cancer ability
Human immunodeficiency virus (HIV) is a retrovirus that infects cells of the human immune system, destroying or damaging its function. There is no symptom at the beginning of HIV infection, but as the infection progresses, the immune system begins to weaken. The final stage of infection is the acquired… Continue Reading Can immunotherapy create a miracle to cure AIDS?
Drug: SA-4-1BBL Magazine: Cancer Research Highlights: A new immunotherapy that promises to prevent multiple cancers T cells play an important role in the defense against cancer, and their activation is regulated by ligand-receptor interactions on macrophages in T cells, dendritic cells, tumor cells, and tumor microenvironments. . These… Continue Reading US scientists confirm for the first time: immunotherapy is expected to prevent multiple cancers
T cells have always been at the center of tumor immunotherapy. In recent years, CAR-T therapy has shown its power to treat certain types of cancer, and the FDA has approved two CAR-T therapies for the treatment of lymphoma or leukemia. At the same time, there are currently hundreds… Continue Reading How will CAR-NK therapy affect the progress of cell therapy?
I The development of immunology has gone through a very long process, and people’s understanding of the immune system has been very shallow for a long time. Although people have long recognized the importance of IL-2 as a cytokine, its role is not known. Studies in the 1960s found that… Continue Reading Tumor immune cell therapy, difficult to move forward
About five or six years ago, the emergence of PD-1/L1 inhibitors triggered a burst of fanaticism in the field of cancer treatment, which can use the immune system to fight cancer by relieving tumor suppression of the human immune system. For a small number of patients, checkpoint inhibitors, including… Continue Reading “Three Great Mountains” for Tumor Immune Combination Therapy
On April 6, Incyte announced a key phase III ECHO – 301 (KEYNOTE – 252) the results of clinical research, according to data epacadostat inhibitor (IDO) joint Keytruda inhibitors (PD – 1) treatment is surgical resection or metastatic melanoma than used alone Keytruda failed to significantly improve progression-free surial (PFS).… Continue Reading After the defeat of IDO, what new progress has been made in the field of small molecule tumor immunotherapy?